PATEL NAIMISH (Chief Medical Officer) sold 19.3% of their position (3.15K shares) of CRISPR THERAPEUTICS AG on the open market
Open‑market sale worth $152.0K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 3/17/2026ACC: 0001193125-26-111286
Officer· Chief Medical Officer
Since Apr 2025
-3.15K
Net shares
Net seller
$152.0K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
8.13K acquired · 11.28K disposed
Non-Derivative Transactions2
Common Shares
Direct
Shares
+8.13K
Price / share
—
Trade value
—
% of position
99.5%
3/14/2026
8.17K→16.29K
Common Shares
Direct
Shares
−3.15K
Price / share
$48.26
Trade value
$152.02K
% of position
19.3%
3/16/2026
16.29K→13.14K
Total
Net shares
+4.97K
Net value
-$152.02K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Shares Direct | 3/14/2026 | M · Option Exercise | +8.13K | — | — | 99.5% | 8.17K | 16.29K |
| Common Shares Direct | 3/16/2026 | S · Sale | −3.15K | $48.26 | $152.02K | 19.3% | 16.29K | 13.14K |
| Total | +4.97K | -$152.02K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Shares
8.13K shares
Shares
−8.13K
Strike price
Held after
24.38K
Exercisable
—
3/14/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Shares8.13K shares | 3/14/2026 | M · Option Exercise | −8.13K | — | 24.38K |